Format

Send to

Choose Destination
Endocrinol Metab Clin North Am. 2016 Mar;45(1):87-100. doi: 10.1016/j.ecl.2015.09.006.

Statins and Diabetes.

Author information

1
Metabolic Sciences, Midwest Center for Metabolic & Cardiovascular Research, 489 Taft Avenue, Suite 202, Glen Ellyn, IL 60137, USA. Electronic address: kmaki@mc-mcr.com.
2
Metabolic Sciences, Midwest Center for Metabolic & Cardiovascular Research, 489 Taft Avenue, Suite 202, Glen Ellyn, IL 60137, USA.
3
Division of Medicine, Charles E. Schmidt College of Biomedical Science, Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431, USA.

Abstract

A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes. The NLA panel advocated following the standards of care from the American Diabetes Association for screening and diagnosis of diabetes, and emphasized the importance of lifestyle modification. This article summarizes NLA's review of the evidence, expanding it to include recent results, and outlines the clinical recommendations.

KEYWORDS:

Cardiovascular disease; Coronary heart disease; Diabetes mellitus; Dyslipidemia; Glucose; Glycemia; High intensity statins; Statins

Republished from

PMID:
26892999
DOI:
10.1016/j.ecl.2015.09.006

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center